Consolidated Edison's forecasted 7.0% annualised revenue growth to the end of 2024 is faster than its historical growth of 5.6% p.a. over the past five years and is expected to outpace the wider industry's forecasted growth of 3.3% per year.
Consolidated Edison's low P/E ratio is due to its forecast for declining earnings. Shareholders accept this as they expect no pleasant surprises in future earnings, implying a stagnant share price.
The mix of low ROE and high debt is unattractive. Consider a company's performance without easy borrowing, as credit markets fluctuate. High-quality firms usually have high ROE and low debt. Future profit growth and required investment should also be considered.
Despite steady reinvestment, Consolidated Edison's unchanged ROCE and increased capital indicates ineffective funds deployment into high-return investments. Hence, multiplying the current value seems unlikely despite prior stock price rise.
Analysts perceive business performance to be as expected, despite missed earnings. Slower revenue growth and expected drop in EPS point to a declining optimism for Consolidated Edison's long-term growth in comparison to peers.
Market seems gloomy about Consolidated Edison even as EPS growth outperforms share price rise. Dividends have enhanced the total shareholder return over five years, offering an optimistic view for dividend-paying stocks. The stock's consistent positive returns might make it worthy of observation.
Pre-Market Stock Movers Gapping up $Wyndham Hotels & Resorts(WH.US)$ (The stock soared over 15% after$精選國際酒店(CHH.US)$, down 6%, disclosed it made an offer to its rival for about $7.8 billion in a cash and stock deal.) $強生(JNJ.US)$ (The stock rose 1.5% after the drugmaker raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $...
QUICK SCALP 92 $ED — STOCK & OPTION PLAY ON THE WATCH: $92.04 🥇 SIGNED OF MORE UPTREND: $92.14 NEED IT TO BREAK OVER: $92.32 key indicator for MORE uptrend $92.55 confirmation uptrend - $92.78 mini breakout - $92.96.$愛迪生聯合電氣(ED.US)$
Gainers: •$根科船務貿易(GNK.US)$+4.7% (positive Barrons article) •$NextDecade(NEXT.US)$+4.7% (files for 4618226 share common stock offering by selling shareholder) •$COMPASS Pathways(CMPS.US)$+4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting) •$Canoo(GOEV.US)$+3.5% (files for 48043111 share common stock offering by selling shareholder) •$American Axle & Mfg(AXL.US)$+3.7% (pr...
愛迪生聯合電氣股票討論區
專欄Today's Pre-Market Stock Movers and Top Ratings: BAC, WH, JNJ, LMT and More
Gapping up
$Wyndham Hotels & Resorts(WH.US)$
(The stock soared over 15% after $精選國際酒店(CHH.US)$ , down 6%, disclosed it made an offer to its rival for about $7.8 billion in a cash and stock deal.)
$強生(JNJ.US)$
(The stock rose 1.5% after the drugmaker raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $...
ON THE WATCH: $92.04
🥇 SIGNED OF MORE UPTREND: $92.14
NEED IT TO BREAK OVER: $92.32
key indicator for MORE uptrend $92.55
confirmation uptrend - $92.78
mini breakout - $92.96. $愛迪生聯合電氣(ED.US)$
專欄Today's pre-market stock movers: BNTX, JPM, RIVN, HPQ and more
• $根科船務貿易(GNK.US)$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US)$ +3.7% (pr...
暫無評論